Open Letter to the General Public on the Quad-Regulator Joint Policy for Prescribing and Dispensing Opioids

October 15, 2014

Dear Colorado citizens:

We, the Chairs and Presidents of the regulatory Boards for dental, medical, nursing and pharmacy in Colorado and the Nurse-Physician Advisory Taskforce for Colorado Healthcare, encouraged the development of the joint Policy for Prescribing and Dispensing Opioids to support practitioner to compassionately treat pain while addressing the prescription drug abuse crisis in our State. This letter discusses the history of the policy and some of the categories of comments received by stakeholders. We hope it provides useful background to the public about our decisions, and we look forward to continuing to work with the community to address this important challenge facing our State.

History

Facilitated by the Nurse-Physician Advisory Task Force for Colorado Healthcare (NPATCH) at the Department of Regulatory Agencies, the Quad-Regulator Boards of Dental, Medical, Nursing and Pharmacy held a workshop in September 2013 to discuss the growing concern of access to pain management and prescription drug misuse and abuse in Colorado. At this workshop, and in conjunction with the recently published Colorado Plan to Reduce Prescription Drug Abuse issued by the Governor as part of his commitment to make Colorado the healthiest state, the Quad-Regulator Boards agreed to pursue a joint policy for prescribing and dispensing painkillers. We agreed that as healthcare increasingly is being delivered in team-based settings, so should the State’s regulation keep pace, and that shared guidance to address such an important public health problem would be a vital step to support Colorado's practitioners to effectively and safely treat pain. This effort at a joint regulatory policy across professional licensing Boards is the first of its kind in the nation.

A number of drafts of the policy were vetted by the Boards over the course of 16 public meetings during a four month period throughout the winter and spring of 2014 in which written comments and testimony were accepted. The Boards made multiple changes as a result of stakeholder comments to address both general concerns and specific word changes. The policy was revised based on suggestions by multiple representatives from the Colorado Consortium to Reduce Prescription Drug Abuse.

The final draft of the policy was unanimously adopted by the four Boards in June and July 2014. Subsequently it was adopted by the Optometry and Podiatry Boards and endorsed by the Veterinary Board. Collectively, these are all of the Boards in the State with authority over practitioner prescribing and dispensing.

Stakeholder views and comments were essential to the crafting of this policy. The following discussion presents some of the categories of comments received, and how the Boards incorporated those comments in the final policy.
Categories of Comments

Bright Line Thresholds: No other topic was so intensely debated among stakeholders throughout the public consideration of the policy than the bright line thresholds. The thresholds in the policy are duration, dosage and formulation. Specifically, the policy recommends additional safeguards be put in place when prescribing and dispensing exceeds the following evidence-based thresholds that have been associated with adverse outcomes:

- 90 days in duration,
- 120 milligram morphine equivalents dosages, or
- certain formulations such as transdermal or long-acting preparations.

Chronic pain patients in particular expressed concern about drawing any line that could be interpreted to suggest the arbitrary discontinuation of opioid therapy.

We want to ensure that the Board’s message with this policy is clear -- the policy does not draw any line, but rather seeks to educate the practitioner of evidence-based thresholds above which safeguards are indicated. Prescribing and dispensing above the certain thresholds is more likely dangerous indicating additional safeguards to protect the patient. The policy does not suggest the discontinuation of opioid therapy after a threshold is crossed. It does recommend the practitioner closely monitor the pain to detect contraindications such as decreased function or quality of life. Also, by issuing these bright line thresholds in policy rather than Board rule, the Boards acknowledge the importance of clinical judgment in the treatment of pain.

The evidence-based, bright line thresholds are intended in particular to assist the group of practitioners that find themselves treating pain without specializing in pain. Short-term treatment of pain can often lead into longer-term treatment, and at higher doses or riskier delivery methods. These bright lines caution the practitioner to pause, re-evaluate treatment, and institute additional safeguards. Not all patients requiring pain therapy can reasonably be referred to pain specialists, given the number of pain specialists in the State. Thus the policy recommends additional safeguards when crossing the bright line thresholds, and draws on practices established by pain specialists, such as treatment agreements and monitoring, in making these recommendations.

Assessing Risk: Stakeholders raised concerns about the policy’s guidance to conduct a patient risk assessment in all prescribing situations. The Boards received comments that, in some situations, conducting a risk assessment may not be in the best interest of the patient or would be burdensome to workflow. Other concerns were raised that the recommended risk assessment was not specific enough to adequately screen for substance and alcohol use.

The Boards determined that the policy should include guidance to conduct a brief risk assessment before initiating opioid therapy, even for very short-term treatment of acute pain, such as dental procedures. Simply put, the risk for adverse outcomes is too high when opioids are used in the presence of evidence-based risk factors, such as history of substance use, or currently prescribed benzodiazepines. Protecting the patient from adverse outcomes is in the best interest of the patient. Items flagged during a brief risk assessment may point to the need for a more sophisticated screening. Practitioners will utilize clinical judgment to tailor the risk assessment to each patient and practice setting, and the policy appendix provides resources for risk assessment instruments.

Classifying Pain: The Boards received a number of comments and requests to define and distinguish the type of pain addressed in this policy, particularly acute versus chronic. Suggestions included limiting the policy to treatment of “chronic” pain.

Because pain can evolve from a more acute phase to a chronic phase, the Boards determined that it was most appropriate to craft a policy that applied to more than just chronic pain. The Boards
determined that risk screening, including checking the PDMP, is essential before prescribing even a few pills for an acute condition.

Moreover, because of the lack of uniformity around what constitutes chronic treatment, the Boards through their examination of many complaints about treatment, determined that many practitioners do not recognize when they have crossed one of the bright lines for which prescribing opioids has been associated with adverse outcomes (dosage, formulation, and duration).

For these reasons, the Boards did not limit the policy to treatment of chronic pain. Note, however, that the Boards did exclude treatment of cancer pain and similar conditions.

On-going evaluation

The Quad-Regulator Policy for Prescribing and Dispensing Opioids is written to address today’s crisis in prescription drug misuse and abuse in Colorado. We, the Chairs and Presidents of the Quad-Regulator Boards are pleased to present a policy that is authentically Coloradan, addressing Colorado’s unique patients, practitioners and settings. It is a living document; however, as science, pharmaceuticals, illness and technology all evolve over time, demanding changes to the way we practice. The Boards are committed to evaluate the effectiveness and usefulness of the policy, including responding to any unintended consequences it may create. Continued collaboration with other state agencies, researchers, practitioners, and patients, facilitated by the 200-member strong Colorado Consortium for Prescription Drug Abuse Prevention, will help to identify and evaluate the outcomes of this policy. Likewise, we welcome continued feedback from all members of the public. Thank you for your interest.

Sincerely (in alphabetical order by Board),

Steven Tilliss, DDS, MS
President, Colorado Dental Board

Mark Watts, MD
President, Colorado Medical Board

Vicki Erickson, RN, NP, PhD
President, State Board of Nursing

Luis Rivera-Lleras, RPh
President, State Board of Pharmacy

Mary Ciambelli, RN, CNS, PhD
Co-Chair, Nurse-Physician Advisory Task Force for Colorado Healthcare

Susan Townsend, MD
Co-Chair, Nurse-Physician Advisory Task Force for Colorado Healthcare
Policy for Prescribing and Dispensing Opioids

Colorado Dental Board, Colorado Medical Board, State Board of Nursing, and State Board of Pharmacy

In collaboration with the Nurse-Physician Advisory Task Force for Colorado Healthcare
PREAMBLE

Prescribing and dispensing medication for the appropriate treatment of pain is a priority for Colorado healthcare providers. However, in 2013 the misuse and abuse of prescription opioids became a public health epidemic in the United States in general, and Colorado in particular, leading to drug addiction, death from overdose, and increased costs to society.

In order to address this crisis, the Colorado Dental Board, Colorado Medical Board, State Board of Nursing, State Board of Pharmacy, and the Nurse-Physician Advisory Task Force for Colorado Healthcare collaborated to identify opportunities and provide meaningful guidance to prescribers and dispensers in Colorado.

The Boards recognize that reversing the trend of opioid misuse and abuse requires coordinated efforts to increase public awareness, take-back events for safe disposal, addiction treatment and recovery options, and enforcement, among others. The Boards and the practitioners they license are one part of a multi-pronged solution.

The Boards recognize the complexities faced by prescribers in the appropriate management of pain. The demands on practitioners considering opioid prescribing differ depending on patient diagnosis, practice settings, and/or conditions. Importantly, long-term therapies addressing cancer-related treatment, palliative and/or hospice care involve different considerations from short-term therapies appropriate for acute or chronic non-cancer pain.

Pain and addiction specialists play an important role in healthcare and the communities they serve to compassionately and safely care for patients. Many of the tools and practices referenced in this policy were developed by such specialists. The need for therapeutic care of pain in Colorado patients exceeds the supply of specialists in the state. However, other types of providers can successfully treat many painful conditions and achieve the function and relief the patient seeks. Accordingly, this policy is intended to educate prescribers and dispensers broadly by providing useful tools that may be utilized at the point-of-care to support clinical decision making.

The Boards further recognize that decreasing opioid misuse and abuse in Colorado should be addressed by collaborative and constructive policies aimed at improving prescriber education and practice, decreasing diversion, and establishing the same guidelines for all opioid prescribers and dispensers. This includes opioid therapies for both acute and chronic non-cancer pain, because

---

1 “Boards” as used in this policy means the Boards overseeing prescribing and dispensing of opioids and involved in the drafting of this policy: the Colorado Medical Board, State Board of Nursing, Colorado Dental Board, and the State Board of Pharmacy.
2 Pain is categorized by a number of descriptors ranging from duration, impact, or physiological response, among others. For the purpose of this policy, the term “chronic, non-cancer pain” is utilized to refer to pain
the Boards find that treatment for pain often does not fall clearly into one category or another.

Diversion and “doctor shopping” accounts for 40% of drug overdose deaths. To address the dual issues of access to appropriate pain management and opioid-related adverse outcomes, prescribers have dual obligations: to manage pain and improve function while reducing problems resulting from misuse and abuse of prescription opioids in the patient and community. Pharmacists share a corresponding responsibility with the prescriber to assure that a prescription order is valid in all respects and is appropriate for the patient and condition being treated.

Therefore, the Boards have agreed to the following guidelines regarding opioid prescriptions in Colorado. Providers prescribing and/or dispensing opioids should:

- Follow the same guidelines
- Use the Colorado Prescription Drug Monitoring Program (PDMP)
- Be informed about evidence-based practices for opioid use in healthcare and risk mitigation
- Educate patients on appropriate use, storage and disposal of opioids, risks and the potential for diversion
- Collaborate within the integrated healthcare team to decrease over-prescribing, misuse and abuse of opioids.

Opioid prescribers and dispensers must conform to the regulations set forth by the respective licensing board and other laws.

To this end, we, the Boards regulating the prescribers and dispensers in Colorado, have developed this joint policy incorporating the guidelines above.

This policy provides guidelines, and does not set a standard of care for prescribers and dispensers. This policy represents the Boards’ current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind Boards or the public. Prescribers may use an alternative approach if the approach satisfies the requirements of the applicable statutes, regulations, and standard of care. The Boards will refer to current clinical practice guidelines and expert review in approaching cases involving the management of pain.

---

that lasts longer than 90 days and is non-terminal. It does not include conditions such as cancer, scleroderma, multiple sclerosis, muscular dystrophy, or rheumatoid arthritis.


4 A “policy” is adopted by a board to provide guidance to licensees regarding the board’s position on various subjects. Policies are unlike statutes or rules in that they are not law. Conversely, “board rules” have the force of law and set forth requirements to which licensees must adhere.
# Table of Contents

**Before Prescribing or Dispensing** ................................................................. 1  
**When Prescribing or Dispensing** ................................................................. 2  
**Prescribing and Dispensing for Advanced Dosage, Formulation or Duration** ....................... 4  
**Patient Education** ......................................................................................... 5  
**Discontinuing Opioid Therapy** ....................................................................... 5
BEFORE PRESCRIBING OR DISPENSING

Develop and maintain competence

Prescribers, including prescribers who dispense, must maintain competence to assess and treat pain to improve function. This includes understanding current, evidenced-based practices and using other resources and tools related to opioid prescribing and dispensing. In some clinical situations consultation with a specialist is appropriate. Pharmacists must maintain competence in the appropriateness of therapy. See the Appendix for a list of resources and tools for developing and maintaining competence.

Utilize safeguards for the initiation of pain management

The decision to prescribe or dispense opioid medication for outpatient use may be made only after a proper diagnosis and complete evaluation which should include a risk assessment, pain assessment, and review of relevant PDMP data. These safeguards apply to acute and chronic, non-cancer pain but not to palliative end-of-life care.

Not all pain requires opioid treatment. Prescribers should not prescribe opioids when non-opioid medication is both effective and appropriate for the level of pain.

1. Diagnose

Prescribers should establish a diagnosis and legitimate medical purpose appropriate for opioid therapy through a history, physical exam, and/or laboratory, imaging or other studies. A bona fide provider-patient relationship must exist.

2. Assess Risk

Prescribers should conduct a risk assessment prior to prescribing opioids for outpatient use and again before increasing dosage or duration. Risk assessment is defined as identification of factors that may lead to adverse outcomes and may include:

- Patient and family history of substance use (drugs including alcohol and marijuana)
- Patient medication history (among other reasons, this is taken to avoid unsafe combinations of opioids with sedative-hypnotics, benzodiazepines, barbiturates, muscle relaxants or to determine other drug-drug interactions)
- Mental health/psychological conditions and history
Policy for Prescribing and Dispensing Opioids

- Abuse history including physical, emotional or sexual
- Health conditions that could aggravate adverse reactions (including COPD, CHF, sleep apnea, elderly, or history of renal or hepatic dysfunction)
- Prescribers and dispensers should observe the patient for any aberrant drug-related behavior and follow-up appropriately when aberrant drug-related behavior is presented. See the Appendix for a description of such behaviors.

See the Appendix for additional resources related to assessment, including resources for alcohol and substance use screening and guidelines for treating patients with risk factors.

If the assessment identifies risk factors, prescribers should exercise greater caution before prescribing opioids as detailed in subsequent sections, consider conducting a drug test or consulting a specialist and put in place additional safeguards as part of the treatment plan.

3. Assess Pain

An appropriate pain assessment should include an evaluation of the patient’s pain for the:
- Nature and intensity
- Type
- Pattern/frequency
- Duration
- Past and current treatments
- Underlying or co-morbid disorders or conditions
- Impact on physical and psychological functioning

4. Review PDMP

Prescribers and dispensers should utilize the Prescription Drug Monitoring Program (PDMP) prior to prescribing or dispensing opioids.

Collaborate with the healthcare team

Prescribers and dispensers should collaborate within the healthcare team to prevent under-prescribing, over-prescribing, misuse and abuse of opioids. See the Appendix for additional resources.

When Prescribing or Dispensing
Verify a provider-patient relationship

A bona fide provider-patient relationship must exist. The prescriber or dispenser should verify the patient’s identification prior to prescribing or dispensing opioids to a new or unknown patient.

For pharmacists, this includes exercising judgment and conducting research if appropriate (such as use of the PDMP or communication with the prescriber or relevant pharmacies) when the prescription order is:

- For a new or unknown patient
- For a weekend or late day prescription
- Issued far from the location of the pharmacy or patient’s residential address
- Denied by another pharmacist.

Additional Safeguards

Ensure the dose, quantity, and refills for prescription opioids are appropriate to improve the function and condition of the patient, at the lowest effective dose and quantity, in order to avoid over-prescribing opioids.

Factors that have been associated with adverse outcomes include: 1) opioid doses greater than 120 mg morphine equivalents per day 2) certain formulations and 3) treatment exceeding 90 days. Additional safeguards have been found to reduce these risks.

Dosage

Opioid doses >120 mg morphine equivalents per day is a dosage that the Boards agree is more likely dangerous for the average adult (chances for unintended death are higher) over which prescribers should use clinical judgment, put in place additional safeguards for the treatment plan (such as utilizing a treatment agreement), consult a specialist or refer the patient; and dispensers should be more cautious. Benzodiazepines are known to potentiate the effects of opioids and may increase the risk of adverse outcomes. See the Appendix for additional resources on dose calculators.

Formulation

In addition to noting and responding to this dosage marker, prescribers and dispensers must use clinical judgment regardless of dose, especially when:

- The prescription is considered an outlier to what is normally prescribed, or

---

Policy for Prescribing and Dispensing Opioids

- Transdermal, extended relief or long-acting preparation is prescribed.

**Duration**

Treatment **exceeding 90 days** should be re-evaluated as opioids may no longer be as effective.

One way to distinguish pain is as either acute (that lasting less than 90 days) or chronic (that lasting 90 days or greater). Management of each presents its own unique challenges. The overwhelming majority of prescribers treat patients with acute pain; in fact the pain for these patients lasts considerably less than 90 days.

If a prescriber extends short-term treatment, and results in exceeding 90 days, prescribers should re-conduct the risk and pain assessments, review the PDMP and undertake the additional safeguards.

**Prescribing and Dispensing for Advanced Dosage, Formulation or Duration**

**Tools and Trials**

Prior to issuing prescriptions that are outliers to the dosage, formulation and duration guidelines described above (for chronic, non-cancer pain), prescribers should determine whether the patient improves functionally on opioids, which could include an opioid trial, and whether the pain relief improves his/her ability to comply with the overall pain management program.

**Monitoring**

The prescribing and dispensing of opioids for chronic pain must be monitored on an ongoing basis, such as:

- assessing for improved function
- rechecking the PDMP, and
- random drug screening according to the prescriber's clinical assessment.

These monitoring tools and others should be documented in a treatment agreement signed by the patient, described more below. Prescribers should not increase an initial opioid dosage without rechecking the PDMP.

**Treatment Agreements**

Prescribers should utilize treatment agreements (also commonly referred to as a plan or contract) and should ensure the patient understands the terms of the agreement. This may be accomplished by having the patient review and sign the
Policy for Prescribing and Dispensing Opioids

treatment agreement.

A treatment agreement often includes information about proper:

- Goals of treatment
- Patient education (proper use, risks of addiction, alternatives)
- Controls (single prescriber, single pharmacy for refills)
- Random drug testing and restrictions on alcohol use
- Storage, disposal, and diversion precautions (including detailed precautions related to adolescents and/or children and visitors to the home).
- Process and reasons for changing/discontinuing the treatment plan; communicating reduction or increase of symptoms; and referring to a specialist.

See the Appendix for resources on sample agreements.

**Patient Education**

Prescribers should educate patients regardless of the dosage, formulation and duration of opioid therapy on proper use, risks of addiction, alternatives, storage, and disposal of opioids and the potential for diversion (see the Appendix for resources on disposal). Risks may include but are not limited to: overdose, misuse, diversion, addiction, physical dependence and tolerance, interactions with other medications or substances, and death.

Pharmacists should offer to review information with the patient about risks, disposal, and other applicable topics.

Providers should educate patients about the risks and benefits of medications that exceed the dosage, formulation and duration guidelines indicated above which may place them at increased risk for long-term dependence and unintended adverse drug effects. Patients who have a previous history of substance use disorder (including alcohol) are at elevated risk.

When alerted to these risk factors, patients can make more informed decisions about their healthcare treatment. For example, some patients have reduced or forgone opioids when alerted to the risk factors. If a decision is made to continue with opioid therapy, a satisfactory response to treatment would be indicated by a reduced level of pain, increased level of function and/or improved quality of life. The use of an interdisciplinary team and family members may be considered as a part of the treatment plan and ongoing monitoring.

**Discontinuing Opioid Therapy**

The prescriber should consider discontinuing opioid therapy when:

- The underlying painful condition is resolved;
Policy for Prescribing and Dispensing Opioids

- Intolerable side effects emerge;
- The analgesic effect is inadequate;
- The patient’s quality of life fails to improve;
- Functioning deteriorates; or
- There is aberrant medication use.

The prescriber discontinuing opioid therapy should employ a safe, structured tapering regimen through the prescriber or an addiction or pain specialist. There is a risk of patients turning to street drugs or alcohol abuse if tapering is not done with appropriate supports. Prescribers of opioids should be familiar with treatment options for opioid addiction. See the Appendix for tips on tapering.
Preventing diversion through appropriate disposal

In order to prevent diversion, providers should provide information regarding appropriate disposal, including the following:

- Secure unused prescription opioids until such time they can be safely disposed. Specifically, ensure that prescription opioids are not readily accessible to other family members (including adolescents and/or children) or visitors to the home.

- Take-back events are preferable to flushing prescriptions down the toilet or throwing them in the trash. Only some medications may be flushed down the toilet. See the FDA’s guidelines for a list of medications that may be flushed: [www.fda.gov](http://www.fda.gov)

- Utilize take-back events and permanent drop box locations

- Utilize DEA disposal guidelines if take-back or drop boxes are unavailable. Those guidelines include:
  
  - Take the drugs out of their original containers and mix them with an undesirable substance, such as used coffee grounds or kitty litter; then put them in a sealable bag, empty can, or other container to prevent the medication from leaking out of a garbage bag;
  
  - Before throwing out a medicine container, tell the patient to scratch out all identifying information on the prescription label to protect their identity and personal health information; and
  
  - Educate patients that prescriptions are patient specific. Patients may not share prescription opioids with friends, family or others and may pose serious health risks, including death.

- Use activated charcoal absorption technologies to inactivate unused medications or used fentanyl patches.

Record keeping

Prescribers who treat patients with opioids should maintain accurate and complete medical records according to the requirements set forth by their licensing board.

Discontinuing/tapering opioid therapy

Weaning from opioids can be done safely by slowly tapering the opioid dose and taking into account several factors related to risk, symptom, and alternatives.
Opioid Taper Plan and Calculator:

Withdrawal Symptoms Assessment:
“Clinical Opiate Withdrawal Scale” The National Alliance for Advocates for Buprenorphine Treatment. Online at: www.naabt.org

Aberrant drug-related behavior

Prescribers and dispensers should use clinical judgment when aberrant drug-related behaviors are observed. Such behavior should be reported to the proper authorities and/or healthcare team as appropriate.

Aberrant drug-related behaviors broadly range from mildly problematic (such as hoarding medications to have an extra dose during times of more severe pain) to felonious acts (such as selling medication). These are any medication-related behaviors that depart from strict adherence to a prescribed therapeutic plan of care.

Prescribers and dispensers should observe, monitor and take precautionary measures when a patient presents aberrant drug-related behaviors such as:

- Requesting early and/or repeated refills
- Presents at or from an emergency department seeking high quantities of a prescription
- Denied by other prescribers or dispensers
- Presents what is suspected to be a forged, altered or counterfeit prescription.
- Forging prescriptions
- Stealing or borrowing drugs
- Frequently losing prescriptions
- Aggressive demand for opioids
- Injecting oral/topical opioids
- Unsanctioned use of opioids
- Unsanctioned dose escalation
- Concurrent use of illicit drugs
- Failing a drug screen
- Getting opioids from multiple prescribers
- Recurring emergency department visits for chronic pain management*

Prescribers and dispensers should be alert for subjective behaviors such as being nervous, overly talkative, agitated, emotionally volatile, and evasive, as these may be signs of a psychological condition that may be considered in a treatment plan.
Policy for Prescribing and Dispensing Opioids

or could suggest drug misuse.**


Practitioner Considerations

Healthcare team:
Consider that the patient may be receiving opioids from another prescriber. Contact the patient’s healthcare team when appropriate which may include the following:
- Physician
- Specialist (pain, addiction, etc.)
- Dentist
- Advanced Practice Nurse (APN)
- Physician assistant
- Pharmacists
- Area emergency rooms
- Surrounding (within 5 miles) or historical pharmacies

Authorities:
- If the prescriber or dispenser suspects illegal activity, the matter should be referred to the Drug Enforcement Agency (DEA) and local law enforcement.
- If a prescriber or dispenser suspect illegal activity on behalf of another prescriber or dispenser, at a minimum, the matter should be reported to the appropriate licensing board.

Prescribers and dispensers should be aware that:
- There is no legal obligation to prescribe or dispense a prescription; and,
- Colorado law strongly encourages prescribers and dispensers of opiate antagonists “to educate persons receiving the opiate antagonist on the use of an opiate antagonist for overdose, including but not limited to instructions concerning risk factors for overdose, recognition of overdose, calling emergency medical services, rescue breathing and administration of an opiate antagonist.” (Section 18-1-712(3)(b), C.R.S.)

Additional Resources and Tools

Establishing and maintaining competence:
Policy for Prescribing and Dispensing Opioids

**Functional and pain assessment:**
“Functional Assessment” Colorado Division of Workers Compensation

**Patient agreements:**
“Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP - R)”
PainEDU.org Online at: www.painedu.org

**Pain tool kit:**
Various resources for assessing and managing pain including risk assessments, patient agreements, dose and conversion calculators among others.

Center for Worker Health and Environment, Colorado School of Public Health. Online at: http://www.ucdenver.edu/academics/colleges/PublicHealth/research/centers/maperc/online/Pages/Pain-Management-CME.aspx

**Substance use screening and brief counseling:**
SBIRT Colorado
www.ImprovingHealthColorado.org

**Drug abuse resources:**
Substance Abuse and Mental Health Services Administration: www.samhsa.gov